Differential analysis of serum proteomics in Crohn’ s disease treated with infliximab
10.3969/j.issn.1000-4718.2015.05.022
- VernacularTitle:英夫利西单抗治疗克罗恩病黏膜愈合的血清差异蛋白质表达研究
- Author:
Shiyue LIAO
;
Baili CHEN
;
Kunhua HU
;
Peisi RAO
;
Yao HE
;
Mingtao LI
;
Minhu CHEN
;
Zhirong ZENG
- Publication Type:Journal Article
- Keywords:
Crohn’ s disease;
Infliximab;
Proteomics;
Mucosal healing;
Serum
- From:
Chinese Journal of Pathophysiology
2015;(5):894-899
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To identify the serum proteins that might serve as biomarkers for predicting mucosal healing ( MH) in the patients with Crohn’ s disease ( CD) treated with infliximab ( IFX) .METHODS:We collected serum sam-ples before treatment (0 week, group A) and 14 weeks after treatment (group B) from 7 CD patients with IFX treatment who had achieved MH, as well as the serum samples from 7 CD patients who had not achieved MH (0 week, group C;14 weeks, group D) .Two-dimensional fluorescence difference gel electrophoresis was applied to analyze and compare the re-sults of serum profiles between groups A and B, C and D, A and C, B and D.Matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry and bioinformatics tools were utilized to preliminarily identify and figure out the dif-ferentially expressed proteins.RESULTS:(1) In total, there were 44 differentially expressed spots, 36, 3, 10 and 31 differentially expressed spots were detected while comparing A with B, C with D, A with C and B with D, respectively. (2) Among those spots, 17, 2, 2 and 15 proteins were identified, respectively.In total, there were 19 differentially ex-pressed proteins, including apolipoprotein E, apolipoprotein A-I, complement factor H, and so on.(3) Protein functional association networks were carried out based on STRING database.CONCLUSION: The serum protein profiles obviously change after IFX treatment in MH CD patients, and the serum protein profiles of MH patients are different from that of non-MH patients after IFX treatment.The 19 proteins we identified may serve as potential biomarkers for predicting MH in CD patients with IFX treatment.
